NasdaqGS:INBXBiotechs
Does Stifel’s Focus on Ozekibart Milestones Reframe Inhibrx Biosciences' (INBX) Core Oncology Narrative?
In the past week, Stifel Nicolaus initiated coverage on Inhibrx Biosciences Inc, issuing a bullish research note that highlighted the company’s clinical-stage oncology pipeline, including the antibody ozekibart.
The report emphasized upcoming milestones for ozekibart in chondrosarcoma and advanced colorectal cancer as important events for assessing Inhibrx Biosciences’ drug development progress.
Next, we’ll examine how Stifel’s focus on upcoming ozekibart clinical milestones may shape...